LABELS · 342c459f-fe40-4422-bc31-88d16fbbd4df

Ibrance

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-07-06
Captured: 2026-09-09T23:37:42.544548+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

1 INDICATIONS AND USAGE IBRANCE is a kinase inhibitor indicated: • for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1.1 ); or o fulvestrant in patients with disease progression following endocrine therapy. ( 1.1 ) • in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA‑authorized test, following recurrence on or after completing adjuvant endocrine therapy. ( 1.1 ) • in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2‑positive locally advanced or metastatic breast cancer following induction treatment. ( 1.2 ) 1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test, following recurrence on or after completing adjuvant endocrine therapy. 1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.

Full extracted label fields

application numbers

NDA212436

boxed warning exact

brand names

Ibrance

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89a142d5-7e61-48bf-9e77-e2cd124c4792

generic names

PALBOCICLIB

342c459f-fe40-4422-bc31-88d16fbbd4df

indications and usage exact

1 INDICATIONS AND USAGE IBRANCE is a kinase inhibitor indicated: • for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1.1 ); or o fulvestrant in patients with disease progression following endocrine therapy. ( 1.1 ) • in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA‑authorized test, following recurrence on or after completing adjuvant endocrine therapy. ( 1.1 ) • in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2‑positive locally advanced or metastatic breast cancer following induction treatment. ( 1.2 ) 1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test, following recurrence on or after completing adjuvant endocrine therapy. 1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.

indications and usage tables exact

is original packager

true

manufacturer names

U.S. Pharmaceuticals

matched search terms

cancer

package ndcs

63539-284-07
63539-284-03
63539-486-07
63539-486-03
63539-688-07
63539-688-03

product ndcs

63539-284
63539-486
63539-688

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

Indications and Usage ( 1.1 , 1.2 ) 6/2026 Dosage and Administration ( 2.1 , 2.2 ) 6/2026

record type

complete_spl_indications_section_candidate

routes

ORAL

rxcuis

2284102
2284104
2284105
2284106
2284107
2284108

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00100.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · indication intro context

application numbers

NDA212436

brand names

Ibrance

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
incomplete_colon_led_indication_intro

clinical review status

pending

content role

indication_intro_context

context span

end: 264
end exclusive: true
exact text: 1 INDICATIONS AND USAGE IBRANCE is a kinase inhibitor indicated: • for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an arom
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 0

current approval status

not_reconciled

duplicate text group

dup-6041bfa991e9d8718655

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-8f52d34500e472f75e5d

label id

342c459f-fe40-4422-bc31-88d16fbbd4df

positive predicate support span

end: 63
end exclusive: true
exact text: is a kinase inhibitor indicated
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 32

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 64
end exclusive: true
exact text: 1 INDICATIONS AND USAGE IBRANCE is a kinase inhibitor indicated:
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22342c459f-fe40-4422-bc31-88d16fbbd4df%22

spl effective date

2026-07-06

spl set id

89a142d5-7e61-48bf-9e77-e2cd124c4792

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 2 · positive indication candidate

application numbers

NDA212436

brand names

Ibrance

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 606
end exclusive: true
exact text: 1 INDICATIONS AND USAGE IBRANCE is a kinase inhibitor indicated: • for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1.1 ); or o fulvestrant in patients with disease progression following endocrine therapy. ( 1.1 ) • in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic brea
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 0

current approval status

not_reconciled

duplicate text group

dup-abaac18236847fd99989

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-5a5e3f56e9e5b17cc0ec

label id

342c459f-fe40-4422-bc31-88d16fbbd4df

positive predicate support span

end: 63
end exclusive: true
exact text: is a kinase inhibitor indicated
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 32

qualifier mentions

context exact
• for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth
kind
age
polarity
not_inferred
span
end
102
end exclusive
true
exact text
adult patients
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
88
context exact
or (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as ini
kind
biomarker
polarity
not_inferred
span
end
226
end exclusive
true
exact text
HER2)-negative advanced or metastatic breast
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
182
context exact
e, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine
kind
stage_or_setting
polarity
not_inferred
span
end
240
end exclusive
true
exact text
advanced or metastatic breast cancer in com
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
197
context exact
ptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1.1 ); or o fulvestrant in patients with disease progression
kind
regimen
polarity
not_inferred
span
end
318
end exclusive
true
exact text
in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
234

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 406
end exclusive: true
exact text: • for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1.1 ); or o fulvestrant in patients with disease progression following endocrine therapy.
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 65

source url

https://api.fda.gov/drug/label.json?search=id%3A%22342c459f-fe40-4422-bc31-88d16fbbd4df%22

spl effective date

2026-07-06

spl set id

89a142d5-7e61-48bf-9e77-e2cd124c4792

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 3 · unclassified context

application numbers

NDA212436

brand names

Ibrance

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 614
end exclusive: true
exact text: r metastatic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1.1 ); or o fulvestrant in patients with disease progression following endocrine therapy. ( 1.1 ) • in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cance
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 207

current approval status

not_reconciled

duplicate text group

dup-af068b495f5683333754

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-503ed9e92f2912b904d5

label id

342c459f-fe40-4422-bc31-88d16fbbd4df

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 414
end exclusive: true
exact text: ( 1.1 )
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 407

source url

https://api.fda.gov/drug/label.json?search=id%3A%22342c459f-fe40-4422-bc31-88d16fbbd4df%22

spl effective date

2026-07-06

spl set id

89a142d5-7e61-48bf-9e77-e2cd124c4792

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · positive indication candidate

application numbers

NDA212436

brand names

Ibrance

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 927
end exclusive: true
exact text: atic breast cancer in combination with: o an aromatase inhibitor as initial endocrine-based therapy ( 1.1 ); or o fulvestrant in patients with disease progression following endocrine therapy. ( 1.1 ) • in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA‑authorized test, following recurrence on or after completing adjuvant endocrine therapy. ( 1.1 ) • in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2‑positive locally advanced or metast
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 215

current approval status

not_reconciled

duplicate text group

dup-de478a2d8959224aa7ef

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-210d9bbe2cd530419a5d

label id

342c459f-fe40-4422-bc31-88d16fbbd4df

positive predicate support span

end: 63
end exclusive: true
exact text: is a kinase inhibitor indicated
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 32

qualifier mentions

context exact
nation with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER
kind
age
polarity
not_inferred
span
end
499
end exclusive
true
exact text
adult patients
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
485
context exact
r the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic
kind
biomarker
polarity
not_inferred
span
end
541
end exclusive
true
exact text
PIK3CA -mutated
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
526
context exact
nts with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected
kind
biomarker
polarity
not_inferred
span
end
569
end exclusive
true
exact text
HER2-negative
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
556
context exact
A -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA‑authorized test, following recurrenc
kind
biomarker
polarity
not_inferred
span
end
615
end exclusive
true
exact text
metastatic breast cancer
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
591
context exact
ine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA‑authorized test, following recurrenc
kind
stage_or_setting
polarity
not_inferred
span
end
615
end exclusive
true
exact text
locally advanced or metastatic breast cancer
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
571
context exact
uthorized test, following recurrence on or after completing adjuvant endocrine therapy.
kind
stage_or_setting
polarity
not_inferred
span
end
726
end exclusive
true
exact text
adjuvant endocrine therapy
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
700
context exact
• in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA‑authorized test,
kind
regimen
polarity
not_inferred
span
end
596
end exclusive
true
exact text
in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metas
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
417

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 727
end exclusive: true
exact text: • in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA‑authorized test, following recurrence on or after completing adjuvant endocrine therapy.
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 415

source url

https://api.fda.gov/drug/label.json?search=id%3A%22342c459f-fe40-4422-bc31-88d16fbbd4df%22

spl effective date

2026-07-06

spl set id

89a142d5-7e61-48bf-9e77-e2cd124c4792

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 5 · unclassified context

application numbers

NDA212436

brand names

Ibrance

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 935
end exclusive: true
exact text: K3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA‑authorized test, following recurrence on or after completing adjuvant endocrine therapy. ( 1.1 ) • in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2‑positive locally advanced or metastatic bre
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 528

current approval status

not_reconciled

duplicate text group

dup-af068b495f5683333754

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-f164b395ba59176c5e35

label id

342c459f-fe40-4422-bc31-88d16fbbd4df

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 735
end exclusive: true
exact text: ( 1.1 )
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 728

source url

https://api.fda.gov/drug/label.json?search=id%3A%22342c459f-fe40-4422-bc31-88d16fbbd4df%22

spl effective date

2026-07-06

spl set id

89a142d5-7e61-48bf-9e77-e2cd124c4792

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 6 · unclassified context

application numbers

NDA212436

brand names

Ibrance

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1176
end exclusive: true
exact text: tated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA‑authorized test, following recurrence on or after completing adjuvant endocrine therapy. ( 1.1 ) • in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2‑positive locally advanced or metastatic breast cancer following induction treatment. ( 1.2 ) 1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negati
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 536

current approval status

not_reconciled

duplicate text group

dup-879ad8735c218ded07e4

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-d2a918ffd01b71ff191a

label id

342c459f-fe40-4422-bc31-88d16fbbd4df

positive predicate support span

Source null

qualifier mentions

context exact
mab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2‑positive locally advanced or metasta
kind
age
polarity
not_inferred
span
end
868
end exclusive
true
exact text
adult patients
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
854
context exact
e maintenance treatment of adult patients with HR-positive, HER2‑positive locally advanced or metastatic breast cancer following induction treatment.
kind
biomarker
polarity
not_inferred
span
end
931
end exclusive
true
exact text
HER2‑positive locally advanced or metastatic
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
887
context exact
treatment of adult patients with HR-positive, HER2‑positive locally advanced or metastatic breast cancer following induction treatment.
kind
stage_or_setting
polarity
not_inferred
span
end
952
end exclusive
true
exact text
locally advanced or metastatic breast cancer follow
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
901
context exact
• in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2‑positive locally advanced or metastatic breast cancer following induction treatment.
kind
regimen
polarity
not_inferred
span
end
917
end exclusive
true
exact text
in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2‑positive locally advanced
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
738

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 976
end exclusive: true
exact text: • in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2‑positive locally advanced or metastatic breast cancer following induction treatment.
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 736

source url

https://api.fda.gov/drug/label.json?search=id%3A%22342c459f-fe40-4422-bc31-88d16fbbd4df%22

spl effective date

2026-07-06

spl set id

89a142d5-7e61-48bf-9e77-e2cd124c4792

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 7 · unclassified context

application numbers

NDA212436

brand names

Ibrance

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1184
end exclusive: true
exact text: r without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2‑positive locally advanced or metastatic breast cancer following induction treatment. ( 1.2 ) 1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advan
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 777

current approval status

not_reconciled

duplicate text group

dup-f4e74141cd088358fb20

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-3da78d86c12d87be72f8

label id

342c459f-fe40-4422-bc31-88d16fbbd4df

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 984
end exclusive: true
exact text: ( 1.2 )
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 977

source url

https://api.fda.gov/drug/label.json?search=id%3A%22342c459f-fe40-4422-bc31-88d16fbbd4df%22

spl effective date

2026-07-06

spl set id

89a142d5-7e61-48bf-9e77-e2cd124c4792

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 8 · positive indication candidate

application numbers

NDA212436

brand names

Ibrance

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1436
end exclusive: true
exact text: t pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2‑positive locally advanced or metastatic breast cancer following induction treatment. ( 1.2 ) 1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. IBRANCE is indicated in combination with inavolisib and
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 785

current approval status

not_reconciled

duplicate text group

dup-03661b893921e296bcf2

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-e8d39cba11d8adab2bbe

label id

342c459f-fe40-4422-bc31-88d16fbbd4df

positive predicate support span

end: 1048
end exclusive: true
exact text: is indicated
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 1036

qualifier mentions

context exact
tic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth
kind
age
polarity
not_inferred
span
end
1084
end exclusive
true
exact text
adult patients
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
1070
context exact
1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hor
kind
biomarker
polarity
not_inferred
span
end
1033
end exclusive
true
exact text
HER2-Negative Metastatic Breast Cancer IBRAN
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
989
context exact
or (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
kind
biomarker
polarity
not_inferred
span
end
1208
end exclusive
true
exact text
HER2)-negative advanced or metastatic breast
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
1164
context exact
1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (
kind
stage_or_setting
polarity
not_inferred
span
end
1048
end exclusive
true
exact text
Metastatic Breast Cancer IBRANCE is indicated
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
1003
context exact
e, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
kind
stage_or_setting
polarity
not_inferred
span
end
1222
end exclusive
true
exact text
advanced or metastatic breast cancer in com
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
1179
context exact
ptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
kind
regimen
polarity
not_inferred
span
end
1236
end exclusive
true
exact text
in combination with:
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
1216

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1236
end exclusive: true
exact text: 1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with:
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 985

source url

https://api.fda.gov/drug/label.json?search=id%3A%22342c459f-fe40-4422-bc31-88d16fbbd4df%22

spl effective date

2026-07-06

spl set id

89a142d5-7e61-48bf-9e77-e2cd124c4792

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 9 · unclassified context

application numbers

NDA212436

brand names

Ibrance

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1500
end exclusive: true
exact text: s indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 1037

current approval status

not_reconciled

duplicate text group

dup-dc8ab78c37963415f811

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-74d7914a6abbc03f3a8a

label id

342c459f-fe40-4422-bc31-88d16fbbd4df

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1300
end exclusive: true
exact text: • an aromatase inhibitor as initial endocrine-based therapy; or
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 1237

source url

https://api.fda.gov/drug/label.json?search=id%3A%22342c459f-fe40-4422-bc31-88d16fbbd4df%22

spl effective date

2026-07-06

spl set id

89a142d5-7e61-48bf-9e77-e2cd124c4792

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 10 · positive indication candidate

application numbers

NDA212436

brand names

Ibrance

classification reasons

inherited_predicate_from_same_label_section_requires_review
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1580
end exclusive: true
exact text: eptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or meta
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 1101

current approval status

not_reconciled

duplicate text group

dup-20a209e056b08e794a47

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-1adb875edb02fa6acdcb

label id

342c459f-fe40-4422-bc31-88d16fbbd4df

positive predicate support span

end: 1048
end exclusive: true
exact text: is indicated
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 1036

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1380
end exclusive: true
exact text: • fulvestrant in patients with disease progression following endocrine therapy.
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 1301

source url

https://api.fda.gov/drug/label.json?search=id%3A%22342c459f-fe40-4422-bc31-88d16fbbd4df%22

spl effective date

2026-07-06

spl set id

89a142d5-7e61-48bf-9e77-e2cd124c4792

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 11 · positive indication candidate

application numbers

NDA212436

brand names

Ibrance

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1913
end exclusive: true
exact text: vanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test, following recurrence on or after completing adjuvant endocrine therapy. 1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 1181

current approval status

not_reconciled

duplicate text group

dup-cf5f12eee198c4164799

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-af8e4c0462ffbf213428

label id

342c459f-fe40-4422-bc31-88d16fbbd4df

positive predicate support span

end: 1401
end exclusive: true
exact text: is indicated
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 1389

qualifier mentions

context exact
nation with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER
kind
age
polarity
not_inferred
span
end
1484
end exclusive
true
exact text
adult patients
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
1470
context exact
r the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic
kind
biomarker
polarity
not_inferred
span
end
1526
end exclusive
true
exact text
PIK3CA -mutated
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
1511
context exact
nts with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected
kind
biomarker
polarity
not_inferred
span
end
1554
end exclusive
true
exact text
HER2-negative
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
1541
context exact
A -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test, following recurren
kind
biomarker
polarity
not_inferred
span
end
1600
end exclusive
true
exact text
metastatic breast cancer
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
1576
context exact
ine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test, following recurren
kind
stage_or_setting
polarity
not_inferred
span
end
1600
end exclusive
true
exact text
locally advanced or metastatic breast cancer
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
1556
context exact
uthorized test, following recurrence on or after completing adjuvant endocrine therapy.
kind
stage_or_setting
polarity
not_inferred
span
end
1712
end exclusive
true
exact text
adjuvant endocrine therapy
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
1686
context exact
IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test,
kind
regimen
polarity
not_inferred
span
end
1581
end exclusive
true
exact text
in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metas
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
1402

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 1713
end exclusive: true
exact text: IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test, following recurrence on or after completing adjuvant endocrine therapy.
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 1381

source url

https://api.fda.gov/drug/label.json?search=id%3A%22342c459f-fe40-4422-bc31-88d16fbbd4df%22

spl effective date

2026-07-06

spl set id

89a142d5-7e61-48bf-9e77-e2cd124c4792

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 12 · positive indication candidate

application numbers

NDA212436

brand names

Ibrance

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2016
end exclusive: true
exact text: 3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA- authorized test, following recurrence on or after completing adjuvant endocrine therapy. 1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 1514

current approval status

not_reconciled

duplicate text group

dup-27c11c2ddffd0f57d6ca

extraction review status

automated_candidate_pending_source_review

generic names

PALBOCICLIB

ind-span-2ff25f81d3acaebc65ad

label id

342c459f-fe40-4422-bc31-88d16fbbd4df

positive predicate support span

end: 1777
end exclusive: true
exact text: is indicated
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 1765

qualifier mentions

context exact
mab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metasta
kind
age
polarity
not_inferred
span
end
1908
end exclusive
true
exact text
adult patients
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
1894
context exact
1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or wit
kind
biomarker
polarity
not_inferred
span
end
1762
end exclusive
true
exact text
HER2-Positive Metastatic Breast Cancer IBRAN
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
1718
context exact
e maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
kind
biomarker
polarity
not_inferred
span
end
1971
end exclusive
true
exact text
HER2-positive locally advanced or metastatic
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
1927
context exact
1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab
kind
stage_or_setting
polarity
not_inferred
span
end
1777
end exclusive
true
exact text
Metastatic Breast Cancer IBRANCE is indicated
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
1732
context exact
treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
kind
stage_or_setting
polarity
not_inferred
span
end
1992
end exclusive
true
exact text
locally advanced or metastatic breast cancer follow
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
1941
context exact
HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
kind
regimen
polarity
not_inferred
span
end
1957
end exclusive
true
exact text
in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced
label id
342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start
1778

regulatory links

schema version

0.1.0

source batch sha256

fc39a8c5cf96bf95ca20b85578140167b66b2741f7d9217f500d9ba0847ac058

source defined aliases

source span

end: 2016
end exclusive: true
exact text: 1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.
label id: 342c459f-fe40-4422-bc31-88d16fbbd4df
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: c46b538bfd46971af979f7166192a9f996420d1176695d389b5be2ab2fe1cc4a
start: 1714

source url

https://api.fda.gov/drug/label.json?search=id%3A%22342c459f-fe40-4422-bc31-88d16fbbd4df%22

spl effective date

2026-07-06

spl set id

89a142d5-7e61-48bf-9e77-e2cd124c4792

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Preserved source evidence · Not medical advice